Octagon Capital Group served as the sole advisor to Harmony Biosciences in connection with its acquisition of the U.S. rights to Pitolisant from bioprojet Pharma.
Octagon Capital Group served as the sole advisor to Harmony Biosciences in connection with its acquisition of the U.S. rights to Pitolisant from bioprojet Pharma.